Thermo Fisher Scientific ApoB-100 Polyclonal Antibody, Agarose

Applications

Western Blot (WB)

• Tested Dilution: Assay-dependent

Immunoprecipitation (IP)

• Tested Dilution: Assay-dependent

Product Specifications

Target Information

Apolipoprotein B (apoB) in human plasma is a major protein of low-density lipoproteins (LDL) with a molecular mass of approximately 260–500 kDa. ApoB binds to specific receptors on cell membranes and is involved in the removal of LDL and very low-density lipoprotein (VLDL) cholesterol from circulation.

LDL acts as the carrier protein for cholesterol in the blood and binds to its receptor on capillary walls, mediating cholesterol uptake and clearance. In atherosclerotic lesions, oxidatively modified LDL is found, and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptors A and CD36. Oxidized LDL may serve as a marker of atherosclerosis, although the specific changes are not fully defined.

Apolipoprotein B is mainly synthesized in the liver and is a major component of very low-density, intermediate-density, and low-density lipoproteins, as well as lipoprotein(a). It serves as a ligand for the LDL receptor, and elevated levels are associated with premature atherosclerosis. Normal plasma apoB levels are approximately 800 mg/L.

ApoB occurs in plasma as two main isoforms: apoB-48 and apoB-100. Both forms are encoded by a single gene from a single, long mRNA. The shorter apoB-48 results from RNA editing of the apoB-100 transcript at residue 2180 (CAA→UAA), creating a stop codon and early translation termination. Mutations in the ApoB gene or its regulatory region can cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective ApoB.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.